A Prospective, Post-Market, Clinical Follow-up Study of the Incompass™ Total Ankle System
Launched by STRYKER TRAUMA AND EXTREMITIES · Aug 5, 2025
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to follow patients who have had ankle replacement surgery using the Incompass™ Total Ankle System. The main goal is to see how well this ankle implant works over time and to confirm that it is safe. Researchers will look at how patients feel in terms of pain and overall quality of life after surgery. To do this, they will review routine medical images like X-rays or CT scans taken before and after the surgery as part of regular care. It’s important to know that this ankle system is already approved by the FDA and commonly used in surgeries, so nothing in this study is experimental.
Adults aged 21 and older who are good candidates for ankle replacement with the Incompass™ system may be eligible to join. Participants need to be able to understand and follow study instructions, attend follow-up visits, and complete questionnaires about their recovery. People who have certain health issues, infections, or previous failed ankle surgeries won’t be able to join. If you take part, you can expect regular check-ups and reviews of your medical images over the follow-up period to help doctors learn more about how patients recover with this implant. This study will help provide important information about the long-term success and safety of the Incompass™ ankle replacement.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The participant must be willing and able to sign a written approved informed consent form (ICF) approved by Institutional Review Board (IRB) or Ethics Committee (EC)
- • 2. Participants must be males or non-pregnant females aged 21 years or older at the time of surgery;
- • 3. Willing and able to comply with the requirements of the clinical investigation plan (CIP), including attend all required study visits.
- • 4. The participant must be able to follow instructions and deemed capable of completing clinical investigation questionnaires.
- • 5. Considered a candidate for total ankle replacement with the Incompass Total Ankle System in accordance with its legally approved Indication for Use (IFU).
- Exclusion Criteria:
- • 1. Participant with an ankle condition, as determined by the investigator, to be an inappropriate candidate for total ankle replacement;
- • 2. Participant is currently enrolled in or plans to enroll in any concurrent drug and/or device clinical investigation that, in the opinion of the Investigator, may confound results;
- • 3. Any participant that meets the definition of a Vulnerable Subject per ISO 14155 Section 3.44.
- • 4. Participants who have participated previously in this clinical trial and who have been withdrawn.
- • 5. Participant who is, or will be, inaccessible for follow-up
- • 6. Participant is pregnant or intends to become pregnant during the course of the study.
- • 7. Participants with a medical or physical condition that, in the opinion of the Investigator, would preclude safe participation in the clinical investigation.
- • 8. Participants requiring revision total ankle replacement of the ankle being considered for the study;
- • 9. Participants with a failed previous ankle surgery (e.g., takedown fusion)
- • 10. Participants with any infection at the ankle site or infections at distant sites that could migrate to the ankle, including sepsis and osteomyelitis;
- • 11. Participants with compromised vascularity that would inhibit blood supply to the operative site;
- • 12. Neuropathic arthropathy of the joint;
- • 13. Insufficient bone stock or bone quality that cannot provide adequate support of the device;
- • 14. Participants who have documented or suspected sensitivity to the implant materials.
- • 15. Participants with inadequate neuromuscular status or those having poor skin coverage around the joint, which would make the procedure unjustifiable
- • 16. Participant who routinely place excessive loads on their ankle as caused by activity and/or patient weight, per investigator discretion; or
- • 17. Any mental or neuromuscular disorder that would create an unacceptable risk of failure or complications in postoperative care.
About Stryker Trauma And Extremities
Stryker Trauma and Extremities is a leading medical technology company dedicated to advancing innovative solutions for the treatment of trauma and orthopedic conditions. With a strong focus on research and development, Stryker is committed to improving patient outcomes through cutting-edge products and comprehensive clinical trials. The company leverages its expertise in trauma and extremity surgery to deliver safe, effective, and minimally invasive solutions that enhance surgical efficiency and promote rapid recovery. By collaborating with healthcare professionals and leveraging data-driven insights, Stryker Trauma and Extremities aims to set new standards in the field of musculoskeletal care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Rebecca Gibson
Study Director
Stryker Trauma & Extremities
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported